DRUG GUIDELINE

Labetalol (Intravenous Severe Hypertension In Pregnancy)
SCOPE (Area): Maternity Unit, Emergency, ICU, Theatre, (Exclude: Paediatrics Seek Advice), (Exclude: General Wards), (Exclude: Coronary Care Unit)
SCOPE (Staff): Medical, Nursing, Midwifery, Pharmacy
Printed versions of this document SHOULD NOT be considered up to date / current


Exclusions

Paediatrics (seek Paediatrician advice) and General Wards


Preamble

See Appendix 1 for full version of this Drug Guideline.


Related Documents

CPP0119 - Hypertension Disorders In Pregnancy - Pre-Eclampsia/Eclampsia
CPG0110 - Neonatal Hypoglycaemia, Prevention And Management
CPP0222 - User Applied Labelling Of Injectable Medicines, Fluids And Lines
CPP0544 - Intravenous Drug Administration And Classification List
POL0077 - Medication Management
CPP0473 - Alaris Intravenous Infusion System With Guardrails Medication And Fluid Management Software
SOP0001 - Principles Of Clinical Care


References

CRC Press Taylor & Francis Group. (2019). Renal Drug Database. Retrieved September 10, 2019 from
Fahed S et al. Labetalol infusion for refractory hypertension causing severe hypotension and bradycardia: an issue of patient safety. Patient Safety in Surgery 2008;2:13
Hospira Inc. (2011, November). Product Information: Labetalol Hydrochloride Injection. Hospira Inc, Lake Forest, USA.
IBM Corporation. (2019). IBM Micromedex. Retrieved December 22, 2019, from
MIMS Online. (2019, December). MIMS Online, Presolol product information. Retrieved December 22, 2019, from
Monash Health (2019, September). Hypertensive disorders in pregnancy, pre-eclampsia, eclampsia Clinical Guideline. Personal communication received Feb 10, 2020.
Phebra Pty Ltd. (2008). Product Information: Labetalol Hydrochloride Injection Version 06. Phebra Pty Ltd, Lane Cove.
Product Insert (2019). Product Information: Labetalol (Trandate) Injection. Obtained from product insert, SAS stock.
Queensland Government (2015, August). Queensland Clinical Guideline – Hypertensive disorders of pregnancy. Accessed on December 22, 2019
Rossi, S. (2019, July). Australian Medicines Handbook. Retrieved December 22, 2019,
SOMANZ (2014, updated June 2015). Guidelines for the Management of Hypertensive Disorders of Pregnancy. Retrieved December 22, 2019 from
The Royal Womens Hospital, Pharmacy Department. (2019). Pregnancy and Breastfeeding Medicines Guide. Retrieved December 22, 2019
The Society of Hospital Pharmacists of Australia. 2024, May. Australian Injectable Drugs Handbook (9th ed.). Retrieved May 20, 2024
The Womens (2018, November). Hypertension - Management of acute. Retrieved December 22, 2019
The Womens (2018, November). Pre-Eclampsia: Management. Retrieved December 22, 2019
Therapeutic Guidelines Limited. (2019, December). Therapeutic Guidelines. Retrieved December 22, 2019, from
Walters Kluwer. (2019) UpToDate, Drug Interaction section. Retrieved December 22, 2019, from


Appendix

Appendix 1 - Labetalol (Intravenous Severe Hypertension in Pregnancy)



Reg Authority: Medication Safety & Governance Committee (MSGC) Date Effective: 21/05/2024
Review Responsibility: Pharmacist - Rotational Date for Review: 30/06/2025
Labetalol (Intravenous Severe Hypertension In Pregnancy) - DRG0035 - Version: 7 - (Generated On: 26-04-2025 05:46)